Biological Products, (No Diagnostic Substances)·LEXINGTON, MA
Financials
20 shown
Type
Period
Ended
Filed
10-Q
Q3 2025
9/30/25
11/10/25
→
10-Q
Q2 2025
6/30/25
8/11/25
→
10-Q
Q1 2025
3/31/25
5/12/25
→
10-K
FY 2024
12/31/24
3/17/25
→
10-Q
Q3 2024
9/30/24
11/12/24
→
10-Q
Q2 2024
6/30/24
8/8/24
→
↓
Earnings Releases (8-K)
28 shown
Filed
Period
11/10/25
Q4 FY2025
→
8/11/25
Q3 FY2025
→
5/12/25
Q2 FY2025
→
3/11/25
Q1 FY2025
→
11/12/24
Q4 FY2024
→
8/8/24
Q3 FY2024
→
↓
News (8-K)
52 shown
Filed
Type
Description
1/16/26
Acquisition
Completion of Acquisition or Disposition of Assets
→
1/14/26
Exec Change
Departure or Appointment of Directors or Certain Officers
→
1/8/26
Agreement
Entry into a Material Definitive Agreement
→
10/9/25
Agreement
Entry into a Material Definitive Agreement
→
9/23/25
Other
Other Events
→
6/20/25
Vote
Submission of Matters to a Vote of Security Holders
→
↓
Prospectuses & Registrations
40 shown
Filed
Form
Description
12/29/25
S-3ASR
S-3ASR
→
8/12/25
S-8
S-8
→
5/12/25
S-3
S-3
→
4/30/25
ARS
ARS
→
8/8/24
424B5
424B5
→
6/25/24
S-8
S-8
→
↓
Filing History(1000 filings)
TypeDateAccessionPeriodSize
4
Mar 9, 2026
0001193125-26-0985284
Mar 6, 2026
7.1 KB
4
Feb 24, 2026
0001193125-26-0669484
Feb 20, 2026
7.1 KB
4
Feb 9, 2026
0001193125-26-0427724
Feb 6, 2026
7.1 KB
4
Jan 26, 2026
0001193125-26-0225614
Jan 23, 2026
7.1 KB
SCHEDULE 13D
Jan 23, 2026
0002106704-26-000001
—
13.6 KB
3
Jan 16, 2026
0001193125-26-0153403
Jan 8, 2026
15.0 KB
8-K
Jan 16, 2026
0001193125-26-0146788-K
Jan 15, 2026
770.2 KB
8-K
Jan 14, 2026
0001193125-26-0129228-K
Jan 8, 2026
145.8 KB
4
Jan 12, 2026
0001193125-26-0103604
Jan 9, 2026
7.1 KB
8-K
Jan 8, 2026
0001193125-26-0077068-K
Jan 3, 2026
139.2 KB
4
Jan 5, 2026
0001193125-26-0023954
Jan 2, 2026
4.7 KB
4
Jan 5, 2026
0001193125-26-0023914
Jan 2, 2026
5.7 KB
S-3ASR
Dec 29, 2025
0001193125-25-335494S-3ASR
—
362.3 KB
4
Dec 29, 2025
0001193125-25-3352884
Dec 26, 2025
7.1 KB
4
Dec 15, 2025
0001193125-25-3191864
Dec 12, 2025
7.1 KB
4
Dec 1, 2025
0001193125-25-3038594
Nov 28, 2025
7.1 KB
4
Nov 17, 2025
0001193125-25-2846004
Nov 14, 2025
7.1 KB
10-Q
Nov 10, 2025
0001193125-25-27455410-Q
Sep 30, 2025
12.6 MB
8-K
Nov 10, 2025
0001193125-25-2732668-K
Nov 10, 2025
336.9 KB
4
Nov 5, 2025
0001193125-25-2668754
Oct 31, 2025
7.1 KB
SCHEDULE 13G/A
Oct 30, 2025
0000102909-25-000038
—
6.0 KB
4
Oct 21, 2025
0001193125-25-2450894
Oct 17, 2025
7.1 KB
8-K
Oct 9, 2025
0001193125-25-2358198-K
Oct 8, 2025
142.3 KB
4
Oct 6, 2025
0001193125-25-2318574
Oct 3, 2025
7.1 KB
4
Oct 3, 2025
0001193125-25-2301004
Oct 1, 2025
4.6 KB
25 filings shown
Proxies
27 shown
Filed
Form
Description
6/6/25
DEFR14A
DEFR14A
→
5/5/25
DEFR14A
DEFR14A
→
4/30/25
DEF 14A
DEF 14A
→
4/18/25
PRE 14A
PRE 14A
→
4/26/24
DEF 14A
DEF 14A
→
2/29/24
DEFA14A
DEFA14A
→
↓
Ownership
40 shown
Filed
Form
Description
3/9/26
4
4
→
2/24/26
4
4
→
2/9/26
4
4
→
1/26/26
4
4
→
1/16/26
3
3
→
1/12/26
4
4
→
↓
Other Filings
40 shown
Filed
Form
Description
1/23/26
SCHEDULE 13D
SCHEDULE 13D
→
10/30/25
SCHEDULE 13G/A
SCHEDULE 13G/A
→
8/29/25
144
144
→
7/29/25
SCHEDULE 13G/A
SCHEDULE 13G/A
→
7/16/25
SCHEDULE 13G/A
SCHEDULE 13G/A
→
5/30/25
EFFECT
EFFECT
→
↓
AGENUS INC — SlamSEC
Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer.